Improving cancer treatment with cyclotron produced radionuclides. Progress report
Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.
- Research Organization:
- Sloan-Kettering Inst. for Cancer Research, New York, NY (United States)
- Sponsoring Organization:
- USDOE, Washington, DC (United States)
- DOE Contract Number:
- FG02-86ER60407
- OSTI ID:
- 10177525
- Report Number(s):
- DOE/ER/60407-6; ON: DE92040305
- Resource Relation:
- Other Information: PBD: 4 Aug 1992
- Country of Publication:
- United States
- Language:
- English
Similar Records
Improving cancer treatment with cyclotron produced radionuclides. [Multiple Drug Resistance (MDR)]
Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy
Related Subjects
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
URIDINE
LABELLING
RADIOPHARMACEUTICALS
CHEMICAL PREPARATION
PROGRESS REPORT
NUCLEAR MEDICINE
RADIOCHEMISTRY
IODINE 124
GALLIUM 66
POSITRON COMPUTED TOMOGRAPHY
IMMUNOGLOBULINS
CYCLOTRONS
RADIOIMMUNOTHERAPY
PATIENTS
FLUORINE 18
550603
400703
EXTERNAL RADIATION IN THERAPY
RADIOISOTOPE PRODUCTION